Kidney Disease As a Risk Factor for Recurrent Cardiovascular Disease and Mortality
Overview
Authors
Affiliations
Background: Chronic kidney disease (CKD) is highly prevalent in the United States and is an independent risk factor for adverse cardiovascular disease (CVD) and all-cause mortality outcomes in patients with acute coronary syndromes. Few studies have evaluated the effect of CKD on cardiovascular events in a diverse community-based population with underlying CVD.
Methods: Data for subjects with preexisting CVD were pooled from 4 publicly available, community-based, longitudinal studies: Atherosclerosis Risk in Communities, Cardiovascular Health Study, Framingham Heart Study, and Framingham Offspring Study. CKD was defined as an estimated glomerular filtration rate less than 60 mL/min/1.73 m2 (<1 mL/s/1.73 m2). The primary study outcome was a composite of myocardial infarction (MI), fatal coronary heart disease (CHD), stroke, and all-cause mortality. The secondary outcome included only MI and fatal CHD.
Results: A total of 4,278 subjects satisfied inclusion criteria, and 759 subjects (17.7%) had CKD. Mean follow-up was 86 months. The primary and secondary outcomes were observed in 1,703 (39.8%) and 857 subjects (20.0%), respectively. Incidence rates for the primary and secondary outcomes were greater in persons with CKD compared with those without CKD (62.5% versus 34.9% and 30.6% versus 17.8%, respectively). Adjusted hazard ratios for the primary and secondary outcomes were 1.35 (95% confidence interval [CI], 1.21 to 1.52) and 1.32 (95% CI, 1.12 to 1.55), respectively.
Conclusion: The presence of CKD in a community-based population with preexisting CVD is associated with an increased risk for recurrent CVD outcomes. This increased risk persists after adjustment for traditional CVD risk factors.
Shriya A, Pawar V, Paul A Curr Diabetes Rev. 2024; 21(6):93-101.
PMID: 38994615 DOI: 10.2174/0115733998305019240702095537.
Zhang Z, Du C, Zhong X, Wang R, Tang L, Liu X Heliyon. 2024; 10(7):e28239.
PMID: 38571641 PMC: 10987917. DOI: 10.1016/j.heliyon.2024.e28239.
Vock D, Helgeson E, Mullan A, Issa N, Sanka S, Saiki A BMC Nephrol. 2023; 24(1):121.
PMID: 37127560 PMC: 10152793. DOI: 10.1186/s12882-023-03149-7.
Allopurinol Lowers Serum Urate but Does Not Reduce Oxidative Stress in CKD.
Sun M, Hines N, Scerbo D, Buchanan J, Wu C, Ten Eyck P Antioxidants (Basel). 2022; 11(7).
PMID: 35883787 PMC: 9312025. DOI: 10.3390/antiox11071297.
Zheng Y, Zhang J, Ren Z, Meng W, Tang J, Zhao S Front Cardiovasc Med. 2022; 9:816011.
PMID: 35811737 PMC: 9260245. DOI: 10.3389/fcvm.2022.816011.